1. James NE, Chichester C, Ribeiro JR. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in Pathogenesis of Epithelial Ovarian Cancer. Frontiers in Oncology. 2018 April;124(8): 1-13.
2. Shahi A, Bahrami N, Fakharian A, Sharifynia S, Moslemi E, et al. Human Epididymis Protein-4 Gene Expression as a Biomarker in patients with Ovarian Cancer in Iran. Open Journal of Clinical Diagnostics. 2017 August;(7): 1-8.
3. Vallius T, Hynninen J, Auranen A, Matomäki J, Oksa S, Roering P, Grènman S. Postoperative human epididymis protrein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. Tumor Biology. 2017 February: 2285-2295
4. Gasiorowska E, Kluz T, Lipski D, Warchoł W, Tykarski A, Nowak-Markwitz E. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors. Disease Markers. 2019 August;(2019): 1-7
5. Fan Q, Luo G, Yi T, Wang Q, Wang D, Zhang G, et al. Diagnostic value of urinary to serum human epididymis protein 4 ratio in ovarian cancer. Biomedical Reports. 2017 April;(7): 67-72.
6. Bianchi V, Mattarozzi M, Giannetto M, Boni A, De Munari I, Careri M. A self calibrating IoT Portable Electrochemical Immunosensor for serum human epididymis protein 4 as a tumor biomarker for ovarian cancer. MDPI. Sensors Journal. 2020 April;(20): 1-12.
7. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world : Epidemiology and risk factors. International Journal of Women's Health. 2019;(11): 287-299.